Gabather AB (5J2)

Overview

Gabather AB (publ), established in 2014 and headquartered in Södertälje, Sweden, positions itself at the forefront of pharmaceutical research and development with a sharp focus on addressing central nervous system diseases. The company is known for its innovative approach to developing drug candidates that show promise for a range of conditions, including anti-psychotics, anti-depressants, anxiolytics, analgesics, and treatments enhancing cognition, particularly for Alzheimer's disease. Dedication to advancing the standards of psychiatric and neurological care underpins Gabather AB's mission, as evidenced by their strategic collaboration with esteemed research institutions like the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup. This partnership aims to propel the progress of their flagship drug candidate, GT-002, through critical stages of clinical assessment.

Products and Services

• Anti-psychotics: Focuses on developing medications aimed at managing symptoms related to psychotic conditions, such as schizophrenia. The development of GT-002, for example, showcases Gabather AB's commitment to offering new therapeutic options for treating schizophrenia.
• Anti-depressants and Anxiolytics: Targets the development of drugs to treat major depressive disorder, among other conditions. These medications are designed to alleviate symptoms of depression and anxiety, showcasing the company's dedication to addressing a broad spectrum of mental health disorders.
• Analgesics: Develops drugs to relieve pain, addressing a crucial need in the healthcare industry. The focus on analgesics demonstrates Gabather AB's recognition of pain management as a fundamental aspect of improving patient quality of life.
• Cognition-Enhancing Treatments: Including drugs for treating Alzheimer's disease. The exploration into cognition-enhancing treatments highlights the company's innovative approach towards combating neurodegenerative diseases and its commitment to long-term patient well-being.
• GT-002: Specifically developed for the treatment of schizophrenia, major depressive disorder, and Alzheimer’s disease. GT-002 represents the culmination of Gabather AB’s research endeavors. The ongoing clinical phase II study in cooperation with the Centre for Neuropsychiatric Schizophrenia Research illustrates the drug's potential impact on mental health treatment paradigms.